ZIMLOVISERTIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H20FN3O4
Molecular Weight	361.3675
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H]1[C@@H](COC2=C3C=C(OC)C(=CC3=CC=N2)C(N)=O)NC(=O)[C@H]1F

InChI

InChIKey=JKDGKIBAOAFRPJ-ZBINZKHDSA-N

InChI=1S/C18H20FN3O4/c1-3-10-13(22-17(24)15(10)19)8-26-18-11-7-14(25-2)12(16(20)23)6-9(11)4-5-21-18/h4-7,10,13,15H,3,8H2,1-2H3,(H2,20,23)(H,22,24)/t10-,13+,15-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H20FN3O4
Molecular Weight	361.3675
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Interleukin-1 receptor-associated kinase 4 9 Target ID: Q9NWZ3 Gene ID: 51135.0 Gene Symbol: IRAK4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28498658	Inhibitor 8504		0.2 nM [IC50]

C_max

Value	Dose	Co-administered	Analyte	Population
64.51 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31805989/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-06650833 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
171.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31805989/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-06650833 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2042 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31805989/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-06650833 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1477 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31805989/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-06650833 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
38.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31805989/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-06650833 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31805989/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-06650833 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:24:02 GMT 2025` Edited by `admin` on `Tue Apr 01 16:24:02 GMT 2025`
Record UNII	S3F315JJXI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

6-ISOQUINOLINECARBOXAMIDE, 1-(((2S,3S,4S)-3-ETHYL-4-FLUORO-5-OXO-2-PYRROLIDINYL)METHOXY)-7-METHOXY-

Preferred Name

English

ZIMLOVISERTIB

Official Name

English

ZIMLOVISERTIB [USAN]

Common Name

English

PF-06650833

Code

English

PF 06650833

Common Name

English

zimlovisertib [INN]

Common Name

English

1-(((2S,3S,4S)-3-ETHYL-4-FLUORO-5-OXOPYRROLIDIN-2-YL)METHOXY)-7- METHOXYISOQUINOLINE-6-CARBOXAMIDE

Systematic Name

English

Zimlovisertib [WHO-DD]

Common Name

English

Code System Code Type Description

DRUG BANK

DB15143